Most Read Articles
5 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

3 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
5 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
3 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.

DAPT discontinuation after PCI safe in patients presenting with acute coronary syndrome

12 Feb 2019

Physician-guided cessation of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is safe in patients presenting with acute coronary syndrome (ACS), a recent study has shown.

The study included 5,018 PCI patients (mean age 63.4 years; 25.4 percent female), of whom 41 percent (n=2,056) presented with ACS. Three modes of DAPT cessation were assessed: discontinuation, interruption and disruption.

Analysis by ACS presentation showed that 2-year DAPT discontinuation rates were comparable between patients with vs without ACS (37.2 percent vs 38.8 percent; p=0.25). In comparison, DAPT in those who presented with ACS was less likely to be interrupted (8.5 percent vs 10.7 percent; p<0.001) but more likely to be disrupted (16.4 percent vs 11.9 percent; p<0.001).

DAPT disruption in ACS-presenting participants was driven mostly by noncompliance (11.6 percent vs 7.6 percent; p<0.001) than by discontinuation due to bleeding complications (5.6 percent vs 4.6 percent; p=0.10).

In terms of outcomes, patients who presented with ACS at baseline were at a significantly higher risk of major adverse cardiovascular events (MACE; 8.12 percent vs 5.43 percent; p=0.0002). This was driven primarily by stent thrombosis (p=0.0006) and spontaneous myocardial infarction (MI; p=0.0002).

When the definition of MACE was narrowed to include only cardiac death, stent thrombosis and MI, researchers found that the corresponding risk was elevated in ACS-presenting patients with DAPT interruption (hazard ratio, 2.72; 95 percent CI, 1.35–5.48). Notably, no such effects were observed for those with DAPT disruption or discontinuation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

3 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
5 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
3 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.